Health technology assessment in Europe
FINN BOERLUM KRISTENSEN Many European countries use health technology assessment (HTA) to assist in making decisions and policies in the health field, and public health and medical decision makers in Europe are now formally building HTA into certain policy, governance, reimbursement, or regulatory processes. A majority of European Union member states now have public sector HTA agencies that provide information for decision-making and policy-making at regional or national levels [1] .
The Tallinn Charter adopted at the Ministerial Conference in the World Health Organization European Region, June 2008, stated that HTA should be used to support more informed decisionmaking [2] , and in July 2008 the European Commission issued a proposal for a directive on the application of patient rights in cross-border healthcare. Article 17 of the proposal concerns cooperation on management of new health technologies, stating that Member States shall facilitate the development and functioning of a network connecting the national authorities or bodies responsible for health technology assessment [3] . In addition, discussion and conclusions on relative effectiveness in the so-called Pharmaceutical Forum lead in the direction of HTA methodology. The Steering Committee of this Forum acknowledged that a European network for HTA could take relative effectiveness assessment of pharmaceuticals forward [4] . Nationally appointed organisations from EU Member States and EFTA/ EEA states are developing a Joint Action on Health Technology Assessment between EU Member States and the European Commission from 2010. This happens under the Work Plan for 2009 for the implementation of the second programme of Community action in the field of health 2008-13. The European network for Health Technology Assessment (EUnetHTA) Collaboration is the basis for this Joint Action [5] . During the years 2006-08 EUnetHTA developed a framework and a suite of practical tools for transnational collaboration in HTA [6] .
What, then, is HTA -how does it relate to policy processes and how does it relate to public health, clinical, and health services research?
Health technology is the application of scientific knowledge in healthcare and disease prevention. Health technology assessment is a multidisciplinary process, which in a systematic, transparent, unbiased, robust manner summarizes information about the medical, social, economic, and ethical issues related to the use of a health technology. Its aim is to inform the formulation of safe, effective health policies that are patient focused and seek to achieve best value. HTA seeks to provide structured, evidence-based input for making decisions on healthcare policy and practices through systematic, interdisciplinary processes. HTA covers all interventions and procedures in healthcare, including diagnostic and treatment methods, medical equipment, pharmaceuticals, rehabilitation, disease prevention methods, and organizational and supportive systems in healthcare. Despite its policy goals, HTA must always be firmly rooted in research and the scientific method [7, 8] .
The role of HTA has been compared with that of a bridge between research and decision-making [9] . There is interdependence, yet division of work, between research-based assessment and decisionmaking. A successful process from a policy question to an HTA report that informs policy spans across paradigms of research and policy in a conscious and transparent way.
Four main streams of applied research methodology have contributed to the development of HTA: policy analysis, evidence based medicine, health economic evaluation and social and humanistic sciences. Policy analysis sets a general framework for HTA as input to policymaking, while evidence based medicine -i.e. clinical and general epidemiology -and health economic evaluation sets the methodological frames for the analyses carried out as part of an HTA. In addition -especially when meeting the requirements of the general definition provided by INAHTA -HTA includes the application of methodologies from social sciences and humanistic research.
Policy analysis
Traditionally policy analysis includes analysis of policy content, policy outputs, and policy processes [10] . HTA needs to enter into the policy processes to be able to fulfil its aim of providing information for decision making. HTA can potentially enter into the policy process at different stages, e.g. agenda setting, policy formulation, or evaluation, but always with the aim of informing the decision.
In systematic policy analysis the following elements are typically included. The input to the analysis is: goals to be achieved, alternatives available for achieving them, and relations between goals and alternatives. The output of the analysis is: tentative conclusions as to which alternate, combination, or allocation is best, and 'what-if' analysis designed to show the effects on the tentative conclusions of changing inputs [11] . If HTA shall successfully include the input elements of policymaking close communication is needed between policy makers, as those most involved in setting the inputs, and HTA producers, as those producing the outputs. This dialogue is essential for an HTA to be effective. Transparency is essential for stakeholders to be ensured that a specific HTA reporting is firmly rooted in research and the scientific method [12] .
Evidence based medicine
Systematic search and review of scientific literature is considered a requirement in contemporary HTA. This requirement is shared with evidence based medicine (EBM). The roots of EBM extend back to the introduction of the scientific method in clinical medicine during the nineteenth century (e.g. the contributions of the Bernard, Koch, Pasteur, and Fibiger in France, Germany and Denmark), and the development of clinical and general epidemiology and systematic review of research literature. However, the concept of EBM was first introduced in a number of seminal journal articles from a group lead from McMaster University in Canada. [13] .
During the eighties work on systematic review in the field of perinatal medicine lead to the publication of the book Effective Care in Pregnancy and Childbirth by a large international group lead from Oxford, UK [14] . The establishment in 1993 of the Cochrane Collaboration has been a key contribution to EBM, and EBM is now well established as a vision and increasingly as a practice in European healthcare [15] .
Health economic analysis
The third main stream that contributed to HTA is health economics. Health economics aims at a societal perspective and emerged as a separate field of economics in the nineteen seventies [16] . Costbenefit analyses had been applied to other public sectors such as transport but the increasing pressure on healthcare budgets lead to the development of academic and practical health economics [17] . Reflecting the diverse needs for economic analysis from institutional to societal level the armamentarium of health economics now ranges from simple cost analyses to cost-effectiveness analyses -in which the effects are measured in clinically relevant parameters, e.g. cost per saved life or cost per avoided strokewhile cost-benefit analyses -in which effects are also valued in monetary units -are undergoing new developments [18] . The methods of health economic analyses are not standardised across Europe. However, best practice is increasingly identifiable while methodology is still being developed and debated in areas such as the incremental costeffectiveness ratio with modelling based on qualityadjusted life years (QALY) [18] . Socioeconomic consequences of e.g. the influence of health technologies on patients' return to the labour market, the need for disability compensation and other economic factors are part of the health economic analysis in HTA. However, HTA does not assess all economical aspects of health technologies. The influence of the degree of application of certain technologies, such as devices or pharmaceuticals, on the Gross Domestic Product (GDP) or providing supporting evidence to increase the competitiveness of certain industries is outside the scope of HTA. These issues should be addressed by other types of macro-economic research but should not be seen as part of HTA.
Social and humanistic sciences
The social and ethical aspects of health technologies cover a range of issues that are not covered by assessment of clinical effectiveness and health economic analysis. Issues under this headline reach from legal issues, issues of the organisation of healthcare, issues of wider societal consequences of health technologies to issues of patient perceptions and ethics. Just like the assessment of effectiveness and cost-effectiveness, the assessment of social and ethical issues should follow a systematic approach. However, the standards and best practice for systematic review is by far most developed when addressing the issues of clinical efficacy and effectiveness in HTA. When it comes to systematically assessing qualitative research into, say, patient or citizen aspects or organisational aspects the review methods of anthropology, sociology and other social sciences are increasingly mobilised [19, 20] . This is reflected in the EUnetHTA HTA Core Model which is a tool that provides a framework for comprehensive analysis of the elements to be included in a robust HTA [21] .
When HTA is increasingly used in formal policy processes across Europe clarity on its role of informing policy and not defining policies or making decisions becomes pertinent. It is important to know where HTA (which is defined as policy analysis) stops, and policy making takes over -or at least where the zone of transfer is -in the process of setting up policies and making decisions. This clarity should be asked from any HTA organisation or regulatory body. Only the word ''assessment'' should be used when describing the HTA work. ''Appraisal'' should be used when and if one wants to describe processes that take HTA and other information into issuing policies (e.g. NICE Guidance in England and Wales) and decisions. Assessment and appraisal have the same meaning in daily language. One should therefore be explicit on the nature of the information: informing policy/or making decisive recommendations for policy/decisions. In some institutions there may be a division of work between units/ departments/groups that (a) make the HTA and (b) make the recommendations/decisions. In such cases the ''product'' coming out of (b) should not be called HTA. They are based on HTA but often take into account other kinds of information and influence (such as local values or available resources).
HTA information is fed into (complex) decisionmaking together with other sorts of reflection that HTA cannot include in the work -without ending up becoming de facto policy making or decisions on policies. That is why there are people doing HTA and people doing policy making, and why the distinction should be as clear as possible for everybody involved -irrespective of any close collaboration between them.
There is a clear distinction in England between assessment (a scientific process and the role of the HTA Programme) and appraisal (the role of policymakers, like the National Institute for Health and Clinical Excellence (NICE)) [22] . The HTA Programme supports all NICE technology appraisals by commissioning independent assessments of the evidence, accompanied by economic evaluation and a review of manufacturers' submissions. These are provided to NICE's appraisal committees to inform its decisions, and are made publicly available once NICE has reached its preliminary decisions. The assessment report does not include a recommendation to the committee.
The distinction between assessment and appraisal may work well in the governance of the England and Wales National Health Service (NHS), but will not per se carry the same clarity outside the NHS.
What is considered to be part of HTA reporting in one country such as stating policy options and their consequences followed by a recommended choice may not be seen as HTA in another, where only stating the policy options would be HTA and the recommendations be policy making. Thus, European collaboration in HTA today must be flexible enough to cover some of the range between ''pure'' research information and giving advice and recommendations.
An increasing body of empirical studies documents considerable impact of HTA reports [23] . Reports were known by a high percentage of their target groups. However, their acceptance varied. The same applied to the ascribed impact on policy decisions. However, the vast majority of studies included in a systematic review were carried out in countries with governmental health systems and a strong, often institutionalised position for HTA, like England, Wales, Sweden, or Canada. All too often the impact of HTAs is still exclusively assessed by its influence on decisions on reimbursements. The review showed that the contribution is much more heterogeneous: HTA reports have had other impacts, including informing stakeholders, structuring dialogue or sensitising recipients on outcome parameters [23] . The review revealed that managing the contribution of HTA reports needs to be done at different levels. The health system needs to institutionalise the role of HTA by integrating it into the decision-making process. If reports are only informative they are very likely to be overlooked. However, the review also showed that often recommendations were accepted at the policy level but eventually not implemented. Clearly spelling out impact objectives can be an important way to support the production of targeted HTA reports. The methodology for assessing the impact of HTA has evolved enormously over recent years. The scope of what is considered to be an impact of HTA has broadened, and the methodology and indicators of the impact of HTA have been refined. Monitoring the impact of HTA reports should therefore become a standard element of the quality assurance portfolio of any HTA agency [23] .
A recent study on HTA and policy making in Europe provided an interesting multiplicity of perspectives from both inside the HTA community and from health systems research and political science [24] . Important issues were raised concerning, on the one hand, the integration of HTA with other efforts to support and improve the quality of a health system (e.g., clinical guideline production, monitoring of healthcare quality) and, on the other, the interrelation between HTA and health services research. Practical considerations on the complex role of HTA are gaining a better theoretical and empirical foothold. However, the field remains theoretically immature, and more multidisciplinary research into the relationship between HTA and health policy is needed to support the practical application of HTA in health systems. HTA is a field in which relatively more practical experience is available concerning the transferability of research to (evidence-based) health policy and the various forms in which research and policy meet structurally. As such, HTA can provide valuable lessons for other areas of health services research, for refining the research agenda and strengthening the linkages between research and policy in the health field. The EU Seventh Framework Programme (FP7) has also identified this issue [25] .
HTA and Health Impact Assessment (HIA) are sometimes mixed up. An editorial in this journal in 2008 explained the HIA concept [26] .
